FDA clears Ocelot catheter for PAD

| | Cardiovascular Business | Vascular & Endovascular

The FDA has cleared Avinger’s Ocelot System, an interventional chronic total occlusion crossing catheter, for sale in the U.S. The system is used to treat patients with peripheral artery disease (PAD).

The Ocelot catheter offers intravascular imaging technology through optical coherence tomography, which allows physicians to cross, see and navigate inside blocked arteries in legs of patients with PAD. The Ocelot catheter is supported by the Lightbox console.

According to Redwood City, Calif.-based Avinger, the FDA reviewed results from the Ocelot CONNECT II trial, which included 122 patients in the U.S.

 

Related Content

IVUS-guided PCI reduces risks in patients with diabetes
LAAC with Watchman FLX reduces bleeding risks after AFib ablation
Bioresorbable BTK stent superior to ballon angioplasty at 2 years
Shockwave Medical’s IVL technology delivers more positive outcomes for PAD patients
Standing desks fail to lower blood pressure or minimize heart risks—they may even do damage
IVL vs. RA for chronic total occlusion PCI: Key data cardiologists should know

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business
What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."